Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · IEX Real-Time Price · USD
34.74
-0.10 (-0.29%)
Apr 22, 2024, 4:00 PM EDT - Market closed
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for COLL stock have an average target of 38.6, with a low estimate of 37 and a high estimate of 40. The average target predicts an increase of 11.11% from the current stock price of 34.74.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for COLL stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +15.14% | Apr 11, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $37 → $40 | Strong Buy | Maintains | $37 → $40 | +15.14% | Feb 26, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $37 → $39 | Buy | Reiterates | $37 → $39 | +12.26% | Feb 23, 2024 |
| Needham | Needham | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +15.14% | Feb 2, 2024 |
| Needham | Needham | Strong Buy Maintains $36 → $40 | Strong Buy | Maintains | $36 → $40 | +15.14% | Jan 4, 2024 |
Financial Forecast
Revenue This Year
595.18M
from 566.77M
Increased by 5.01%
Revenue Next Year
607.83M
from 595.18M
Increased by 2.13%
EPS This Year
3.01
from 1.29
Increased by 133.45%
EPS Next Year
3.74
from 3.01
Increased by 24.30%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 617.8M | 636.1M | 640.8M | 478.6M | 467.0M |
| Avg | 595.2M | 607.8M | 576.5M | 394.5M | 409.6M |
| Low | 567.9M | 568.7M | 506.1M | 347.2M | 351.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 9.0% | 6.9% | 5.4% | -17.0% | 18.4% |
| Avg | 5.0% | 2.1% | -5.2% | -31.6% | 3.8% |
| Low | 0.2% | -4.5% | -16.7% | -39.8% | -11.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.41 | 4.04 | 5.03 | 6.90 | 6.03 |
| Avg | 3.01 | 3.74 | 4.53 | 4.70 | 5.85 |
| Low | 2.55 | 3.38 | 4.01 | 3.34 | 5.63 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 164.5% | 34.2% | 34.4% | 52.3% | 28.4% |
| Avg | 133.5% | 24.3% | 21.0% | 3.7% | 24.7% |
| Low | 97.5% | 12.3% | 7.1% | -26.2% | 19.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.